title: [GEIPC-SEIMC (Study Group for Infections in the Critically Ill Patient of the Spanish Society for Infectious Diseases and Clinical Microbiology) and GTEI-SEMICYUC ( Working Group on Infectious Diseases of the Spanish Society of Intensive Medicine, Critical Care, and Coronary Units) recommendations for antibiotic treatment of gram-positive cocci infections in the critical patient].
abstract: In recent years, an increment of infections caused by gram-positive cocci has been documented in nosocomial and hospital-acquired-infections. In diverse countries, a rapid development of resistance to common antibiotics against gram-positive cocci has been observed. This situation is exceptional in Spain but our country might be affected in the near future. New antimicrobials active against these multi-drug resistant pathogens are nowadays available. It is essential to improve our current knowledge about pharmacokinetic properties of traditional and new antimicrobials to maximize its effectiveness and to minimize toxicity. These issues are even more important in critically ill patients because inadequate empirical therapy is associated with therapeutic failure and a poor outcome. Experts representing two scientific societies (Grupo de estudio de Infecciones en el Paciente Crítico de la SEIMC and Grupo de trabajo de Enfermedades Infecciosas de la SEMICYUC) have elaborated a consensus document based on the current scientific evidence to summarize recommendations for the treatment of serious infections caused by gram-positive cocci in critically ill patients.
authors: Servicio de Medicina Intensiva, Hospital de Galdakao, Vizcaya, (GEIPC), España. pedromaria.olaecheaastigarrag@osakidetza.net
authors: P M Olaechea
authors: PM
authors: Astigarraga
authors: J Garnacho
authors: JG
authors: Montero
authors: S Grau
authors: SG
authors: Cerrato
authors: O Rodríguez
authors: OR
authors: Colomo
authors: M Palomar
authors: MP
authors: Martínez
authors: R Zaragoza
authors: RZ
authors: Crespo
authors: P Muñoz
authors: PM
authors: García-Paredes
authors: E Cerdá
authors: EC
authors: Cerdá
authors: F Alvarez
authors: FA
authors: Lerma
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D002404:Catheterization / Q000009:adverse effects; D002494:Central Nervous System Infections / Q000188:drug therapy / Q000382:microbiology; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D003422:Critical Care / Q000592:standards*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000382:microbiology; D019317:Evidence-Based Medicine; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents